At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 97 enrolled
Drug / intervention
Gepotidacindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3b, Open-label, Single-arm Study in Adolescent and Adult Female Participants to Evaluate Clinical Symptom Improvement and the Safety of Gepotidacin During Treatment of Uncomplicated Urinary Tract Infections (Acute Cystitis)
In Brief
A Phase 3 clinical trial evaluating Gepotidacin for Urinary Tract Infections. Completed, enrolled 97 participants across 22 sites.
Detailed Summary
The study will be conducted to evaluate the clinical symptom improvement and safety of oral gepotidacin for treatment of uncomplicated UTI (acute cystitis) in adolescent and adult female participants.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUrinary Tract Infections
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20252026
First PostedSep 2024
Enrollment StartOct 2024
Primary CompletionMar 2025
TodayJul 2026
First PostedSep 19, 2024
Enrollment StartOct 2, 2024
Primary CompletionMar 10, 2025
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 1.8 years ago
Interventions
Gepotidacindrug
Gepotidacin will be administered.